Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results Jan 22, 2008 |
20.6 KB |
|
|
NEW BRUNSWICK, N.J., Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced record sales of $16.0 billion for the fourth quarter of 2007, an increase of 16.6% as compared to the fourth quarter of 2006. Operational growth was 11.9% and currency contributed 4.7%. Domestic sales were up 9.1%, while internation... |
|||
|
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy Jan 18, 2008 |
17.0 KB |
|
|
BRIDGEWATER, N.J., Jan 18, 2008 /PRNewswire via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the anti-HIV medication INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HI... |
|||
|
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2007 Financial Results Jan 15, 2008 |
5.5 KB |
|
|
NEW BRUNSWICK, N.J., Jan 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. EST on Tuesday, Jan. 22, 2008, to review fourth-quarter and full-year 2007 financial results. William C. Weldon, Chairman and Chief Executive Officer, will host the meeting. Investors and other inte... |
|||
|
IONSYS™, the highly innovative needle-free system for the management of acute post-operative pain, available in Germany, the UK and Ireland Jan 14, 2008 |
10.8 KB |
|
|
Beerse, Belgium (January 14, 2008) - Janssen-Cilag International NV announced today that IONSYS™ (fentanyl iontophoretic transdermal system), a new innovative, needle-free system indicated for the management of acute post-operative pain in a hospital setting, will become available in Germany, the UK and Ireland this week. These countries r... |
|||
|
Court of Appeals Upholds Verdicts in Favor of Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation Jan 7, 2008 |
7.0 KB |
|
|
WARREN, N.J., Jan 07, 2008 /PRNewswire via COMTEX News Network/ -- The Court of Appeals for the Federal Circuit in Washington, D.C. today upheld two separate 2005 jury verdicts that found Medtronic, Inc. and Boston Scientific Corporation infringed coronary stent patents owned by the Cordis Corporation, a Johnson & Johnson company. Cordis now intend... |
|||
|
Supplemental New Drug Application for PREZISTA™ Submitted to U.S. Food and Drug Administration Dec 21, 2007 |
11.3 KB |
|
|
Yardley, PA (December 21, 2007) – Tibotec, Inc., today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the protease inhibitor (PI) PREZISTA™(darunavir), which seeks traditional approval and an expanded indication to include human immunodeficiency vir... |
|||
|
Centocor Inc., Schering-Plough Corporation Revise Agreement Covering REMICADE®, Golimumab Dec 21, 2007 |
7.8 KB |
|
|
Horsham, PA And Kenilworth, NJ. (December 21, 2007) – Centocor, Inc., and Schering-Plough Corporation Corporation (NYSE: SGP), today announced they have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE® (infliximab), an anti-tumor necrosis factor (anti-TNF... |
|||
|
Submission of Marketing Authorisation Application for VELCADE® (bortezomib) in Europe Dec 21, 2007 |
8.7 KB |
|
|
BEERSE, Belgium, December 21, 2007/Belga Newswire/ -- Janssen-Cilag International NV, has submitted a Marketing Authorization Application to the European Medicines Evaluations Agency for the use of VELCADE® (Bortezomib) for the treatment of patients with previously untreated multiple myeloma (MM). Millennium Pharmaceut... |
|||
|
INVEGA™ Shows Favorable Long-Term Safety Profile in a One Year Study of Patients With Schizophrenia Dec 12, 2007 |
12.7 KB |
|
|
Titusville, NJ (December 12, 2007) – INVEGA™ (paliperidone) Extended-Release Tablets showed favorable long-term safety and tolerability during a one-year open-label extension (OLE) study, according to a new, company-sponsored study. In addition, patient symptom scores improved or were stable, on average, over this 52-week study1.... |
|||
|
Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery Dec 10, 2007 |
12.7 KB |
|
|
ATLANTA, Dec 10, 2007 (BUSINESS WIRE) -- Phase III clinical trial results released today underscore that rivaroxaban, the oral, once-daily, investigational anticoagulant, was significantly more effective than enoxaparin, the standard of care, in preventing venous thromboembolism (VTE) in patients undergoing total hip or knee replacement surgery. Ri... |
|||
|
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery Dec 8, 2007 |
9.5 KB |
|
|
ATLANTA, Dec 08, 2007 (BUSINESS WIRE) -- Results from a Phase III trial in patients undergoing total hip replacement surgery presented today showed that administration of the oral, once-daily, investigational anticoagulant, rivaroxaban, was statistically superior to once-daily subcutaneous administration of enoxaparin, the current standard of care ... |
|||
|
Centocor and Janssen-Cilag announced the submission of the US and European filings for ustekinumab (CNTO 1275) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Dec 4, 2007 |
9.2 KB |
|
|
*** Your Title Here *** HORSHAM, Pa. and BEERSE, Belgium, Dec. 4 /PRNewswire/ -- Centocor, Inc. and Janssen-Ci... |
|||
|
FDA Approves the Allergy Treatment Zyrtec® for Use Without a Prescription Nov 16, 2007 |
12.4 KB |
|
|
FT. WASHINGTON, Pa., Nov. 16 /PRNewswire/ -- McNeil Consumer Healthcare, a division of McNEIL-PPC, Inc., announced today that it received approval from the U.S. Food and Drug Administration (FDA) for the allergy treatment ZYRTEC® (cetirizine HCl) to be used without a prescription for adults and children. ZYR... |
|||
|
Johnson & Johnson Announces Changes to Accelerate Growth Nov 15, 2007 |
8.9 KB |
|
|
NEW BRUNSWICK, N.J., Nov 15, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced a series of organizational changes, including the creation of a new strategy and growth organization to sharpen its focus on opportunities outside its traditional areas of interest and in the growing intersections of health care and... |
|||
|
New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology Nov 9, 2007 |
9.3 KB |
|
|
RARITAN, N.J., Nov 09, 2007 (BUSINESS WIRE) -- Findings from three phase III clinical trials of rivaroxaban will be presented in the plenary session and during oral presentations at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, from December 8 to 11, 2007. Rivaroxaban is being jointly developed by Johnson & Johnson Ph... |
|||
|
Johnson & Johnson to Present at the Credit Suisse 2007 Healthcare Conference Nov 6, 2007 |
6.0 KB |
|
|
NEW BRUNSWICK, N.J., Nov 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will present at the Credit Suisse 2007 Healthcare Conference on Tuesday, November 13th at the Arizona Biltmore Hotel. Joseph C. Scodari, Worldwide Chairman, Pharmaceuticals Group, will represent the Company in a session scheduled at 11:30 a.m. Moun... |
|||
|
Pooled Analysis Of Long-Term Data Suggests CYPHER® Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents Nov 5, 2007 |
10.1 KB |
|
|
Orlando, FL (November 5, 2007) – A pooled analysis of the E-SIRIUS and C-SIRIUS trials, called New SIRIUS, found that the CYPHER® Sirolimus-eluting Coronary Stent continued to provide clinical benefits with similar safety compared to a bare metal stent at five-year follow-up. The data are being presented today at the American Heart As... |
|||
|
Johnson & Johnson to Host Analyst Meeting to Discuss Three Late-Stage Pipeline Compounds Presented at American College of Rheumatology (ACR) Conference Nov 1, 2007 |
6.8 KB |
|
|
NEW BRUNSWICK, N.J., Nov 01, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson will sponsor an analyst meeting and webcast for financial analysts on Thursday, November 8, from 5:00-6:00 p.m. (Eastern Time) to coincide with the American College of Rheumatology's annual meeting in Boston. The analyst meeting will be held in the Republic ... |
|||
|
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate Oct 29, 2007 |
12.5 KB |
|
|
TITUSVILLE, N.J., Oct 29, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly atypical antipsychotic intramuscular inject... |
|||
|
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo Oct 26, 2007 |
11.4 KB |
|
|
BOSTON, Oct 26, 2007 /PRNewswire via COMTEX News Network/ -- Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA(R) OROS(R) methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psy... |
|||
= add release to Briefcase
